Page 381 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux
P. 381

342                 MÉDICAMENTS EN RELA DON A VEC DES SYSTÈMES HORMONA UX

             MENDLER S.S. et al. "Probucol, a new therapy for HIV infection" (1992) 8th Int Conf
              AIDS, 3th STD World Congress Amsterdam ; Abstr PO 13 30 19, July 19-24,
              Amsterdam.
            ROUFFY J. "Effet sur les lipides sériques du bis(2-hydroxyéthylthio)-1,10-décane
              (LL1588) et du clofibrate à partir de 91 observations d'hyperlipoprotéinémie pri­
              maire" (1973) Semaine Hôpitaux, Paris, 49 (1), 31-36.
            INHIBITEURS DEL'HMG-CoA RÉDUCTASE
            Articles généraux
            ENDO A. “The discovery and development of HMG-CoA reductase inhibitors" (1992) J
              Lipid Res, 33,1569-1582.
            ‘Les inhibiteurs de l'HMG-CoA réductase" (1992) CNIMH XIII, 4,183-222.
            CAJAB C. “Les inhibiteurs de l'HMG-CoA réductase; aspects récents" (1989) Bull
              Soc Chim Pharm, Lille 45 (2,3), 13-96 ; 45 (4), 1-49.
            Ta-Jyh LEE "Synthesis, SARs and therapeutical potential of HMG-CoA reductase inhi­
              bitors" (1987) Trends Pharmacol Sel, 8, 442-46.
            SHEPHERD J. et al. "Pharmacological approaches to the modulation of plasma cho­
              lestérol" (1988) Trends Pharmacol Sel, 9, 326-329.
            GOUBIER C. et al. “Les inhibiteurs de l'HMG-CoA réductase : une nouvelle classe de
              normolipémiants" (1990) Lyon Pharmaceutique 42 (3), 205-211.
            Préparation, caractéristiques physico-chimiques, données pharmacocinétiques
            NARASAKA K. et al. “Stereoselective réduction of p-hydroxyketones to 1,3-diols ;
              highly sélective 1,3-asymmetric induction via boron chelates" (1984) Tetrahedron,
              40 (12), 2233-2238.
            ROSEN T. et al. "Total synthesis of (+) compactin" (1985) J Chem Soc, 107, 3731­
              3733.
            MOORE R. N. et al. “Biosynthesis of the hypocholestérolémie agent mevinolin by
              Aspergillus terreus. Détermination of the origin of carbon, hydrogen and oxygen
              atoms by 13C NMR and mass spectrometry" (1985) J Am Chem Soc, 107 (12),
              3694-3701.
            HARUYAMA H. et al. "Structure élucidation of the bioactive métabolites of ML-236B
              (mevastatin) isolated from dog urine" (1986) Chem Pharm Bull 34 (4), 1459-1460.
            HEATHCOCK C.H. "Synthesis and biological activity of the hexaline moiety of com­
              pactin (ML-2363)" (1986) Tetrahedron Lett, 27, 4709-4712.
            HEATHCOCK C.H. et al. "Total synthesis and biological évaluation of structural ana-
              logs of compactin and dihydromevinolin" (1987) J Med Chem, 30,1858-1873.
            ASKIN D. et al. "Synthesis of synvinolin : extremely high conversion alkylation of an
             ester enolate" (1991) J Org Chem 56 (16), 4929-4932.
           SATO S. "The structure of monacolin K, C24H36OS. (1984) Acta Cryst, C40, 195-198.
           SATO S. "X-Ray crystal structure of the tert-octylamine sait (RMS-431) of pravastatin"
             (1988) J Antibiotics 41 (9), 1265-1267.
           DANIEWSKI A.R. et al. “Remote diastereoselection in the asymmetric synthesis of
             pravastatin" (1992) J Org Chem, 57 (26), 7133-7139.
           ROTH B.D. et al. “Relationship between tissue selectivity and lipophilicity for inhibitors
             of HMG-CoA reductase" (1991) J Med Chem 34 (1), 463-466.
   376   377   378   379   380   381   382   383   384   385   386